Procaps was founded in Barranquilla, Colombia.

Commercialization of our first Softgel technology, with the launch of our Dolofen brand.

Opening of our offices in Guatemala

Opening of our offices in Dominican Republic.

Beginning of operations in Brazil and offices in Peru.

Opening of our offices in Bolivia

Launch of our R&D Department in Barranquilla, Colombia, and opening of our corporate offices in Miami, USA.

Opening of our offices in Panama

Acquisition of Farmioni, in Bogota, Colombia. Beginning of our Pharmayect business and entrance in the Clinical Specialties segment.

FDA approval for Barranquilla plant, the first plant in LatAm to have approval by the FDA.

Opening of our offices in Honduras and Costa Rica.

Spin off of Diabetrics, a leading diabetes solution and acquisition of the RymcoMedical facility, specialized in single-use medical products such as syringes, needles, infusion equipment, face masks, and surgical clothing

Acquisition of Laboratorios Lopez, Biokemical S.A. de C.V, in El Salvador.

Opening of our offices in Nicaragua.

IPO of Procaps at Nasdaq, through the Business Combination with Union Group, which resulted in our Ordinary Shares and warrants being listed on the Nasdaq Global Market on September 30, 2021 under the symbols “PROC” and “PROCW”, respectively.

Acquisition of the West Palm Beach facility, our first US-based Softgel production facility and R&D center and beginning of construction of our new gummies facility in Miramar, Florida.